Meng Li
5 Papers
4 Citations
Meng Li is an academic researcher. The author has contributed to research in topics: Dupilumab & Medicine. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
Zhaoyang Li,Allen Radin,Meng Li,Jennifer D. Hamilton,Miyuki Kajiwara,John D. Davis,Yoshinori Takahashi,Setsuo Hasegawa,Jeffrey Ming,A. Thomas DiCioccio,Yongtao Li,Pavel Kovalenko,Qiang Lu,Catherine Ortemann‐Renon,Marius Ardeleanu,Brian N. Swanson +15 more
TL;DR: Dupilumab reduced circulating concentrations of total IgE and TARC, indicating blockade of IL‐4Rα–mediated signaling, and had a favorable safety profile across the wide range of doses administered, support the continued development and use of dupilumAB in treatment of type 2 diseases.
56
Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.
John D. Davis,Ashish Bansal,David Hassman,Bolanle Akinlade,Meng Li,Zhaoyang Li,Brian N. Swanson,Jennifer D. Hamilton,A. Thomas DiCioccio +8 more
TL;DR: Blockade of IL‐4/IL‐13 signaling in patients with type 2 inflammation does not appear to significantly affect CYP450 enzyme activities; the use of dupilumab in atopic dermatitis patients is unlikely to influence the pharmacokinetics of CYP 450 substrates.
44
Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data.
Pavel Kovalenko,John D. Davis,Meng Li,Ronda Rippley,Marius Ardeleanu,Brad Shumel,Neil M.H. Graham,Gianluca Pirozzi,Mohamed A. Kamal,A. Thomas DiCioccio +9 more
TL;DR: While antidrug antibodies, albumin, race, body mass index, and Eczema Area and Severity Index score were statistically significant covariates, only body weight had a notable effect on central volume, explaining interindividual variability.
15
Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma.
Li Zhang,Yue Gao,Meng Li,Christine Xu,John D. Davis,Vanaja Kanamaluru,Qiang Lu +6 more
- 01 Aug 2021
TL;DR: In this article, a population pharmacokinetic model was developed using data from healthy subjects and patients with moderate-to-severe asthma receiving intravenous or subcutaneous dupilumab doses.
9
•Journal Article
Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials
Andrew F Alexis,Marta I. Rendon,Jonathan I. Silverberg,David M. Pariser,Benjamin Lockshin,Christopher E.M. Griffiths,Jamie Weisman,Andreas Wollenberg,Zhen Chen,John D. Davis,Meng Li,Laurent Eckert,Abhijit Gadkari,Brad Shumel,Ana B. Rossi,Neil M.H. Graham,Marius Ardeleanu +16 more
TL;DR: Significant clinical improvement and a favorable benefit-risk profile can be achieved with dupilumab treatment in patients of White, Asian, and Black/African American racial subgroups with moderate-to-severe AD inadequately controlled with topical medications.